Urology · El Paso, TX
NPI
1588636633
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
7420 Remcon Cir, Bldg A
El Paso, TX, 79912
Phone (915) 532-8823
Groups this clinician bills Medicare through
Medicare paid, 2023
$464K
10,742 services
Medicare patients, 2023
83
Average age 79
Drug cost, 2024
$6.5M
687 prescriptions
Company payments, 2024
$13.81
From 1 companies
Procedures and visits billed to Original Medicare, 2023
In 2023, the most common Medicare service billed by Daniel C Voglewede was code J0897 (injection, denosumab, 1 mg), 8,160 times for 27 patients. In total Daniel C Voglewede billed 10,742 services in 19 codes, and Medicare paid $464K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,160 | 27 | $18.32 | $150K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 216 | 23 | $131.60 | $28K |
| 99215 Office E&M - Established | Office | 172 | 68 | $132.53 | $23K |
| 96372 Injection Administration | Office | 81 | 26 | $11.02 | $893 |
| 96402 Chemotherapy Administration | Office | 58 | 26 | $26.24 | $1,522 |
| 99214 Office E&M - Established | Office | 21 | 15 | $89.29 | $1,875 |
By year: 2022 $762K for 11,098 services; 2023 $464K for 10,742 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81001 Clinical Chemistry | 70 | 43 | $3.14 | $220 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel C Voglewede prescribed most often to Medicare patients was Erleada (Apalutamide), with 225 prescriptions and refills. In total Daniel C Voglewede wrote 687 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Erleada Apalutamide | 225 | 225 | 46 | $3.2M |
| Xtandi Enzalutamide | 126 | 126 | 24 | $1.7M |
| Orgovyx Relugolix | 90 | 90 | 15 | $233K |
| Nubeqa Darolutamide | 82 | 82 | 16 | $1.1M |
| Prednisone Generic | 43 | 49 | Under 11 | $137 |
| Abiraterone Acetate Generic | 38 | 38 | Under 11 | $17K |
| Methylprednisolone Generic | 15 | 15 | Under 11 | $194 |
| Yonsa Abiraterone Acet,submicronized | 15 | 15 | Under 11 | $149K |
Brand drugs: 558 claims; generic drugs: 129 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Daniel C Voglewede $13.81 ($13.81 in general payments such as food, travel and fees) from 1 company. The largest payer was Boston Scientific Corporation with $13.81.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 1 | $13.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.